Alebund Pharmaceuticals (Jiangsu) Limited (HKG:9637)
Hong Kong · Delayed Price · Currency is HKD 28.96
-1.00 (-3.34%)
Last updated: Jul 16, 2026, 10:39 AM HKT
Alebund Pharmaceuticals (Jiangsu) Company Description
Alebund Pharmaceuticals (Jiangsu) Limited operates as a biopharmaceutical company that develops therapies for kidney diseases and their complications in China and Hong Kong.
Its products include AP301, a phosphate binder; AP306, a sodium-dependent phosphate transport protein inhibitor; one early-clinical-stage product candidate AP303; and four preclinical product candidates, including AP308, AP304, AP305, and AP307.
Alebund Pharmaceuticals (Jiangsu) Limited was founded in 2018 and is headquartered in Yangzhou, China.
Alebund Pharmaceuticals (Jiangsu) Limited
| Country | China |
| Founded | 2018 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Guoyao Xia |
Contact Details
Address: Building 7 Yangzhou China | |
| Website | alebund.com |
Stock Details
| Ticker Symbol | 9637 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guoyao Xia | Chief Executive Officer |
| Yongli Liu | Chief Financial Officer |
| Huading Zhang | Chief Operating Officer |